Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

benzinga.com/news/health-care/25/07/46501475/viatris-hits-snag-in-eye-drug-study-phase-3-plans-under-review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. (NASDAQ:VTRS) on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects…

This story appeared on benzinga.com, 2025-07-18 18:17:12.
The Entire Business World on a Single Page. Free to Use →